T. lt； P gt； present invention； oacute； n refers to the anti receptor antibody or a sleeping drug transferred by human； Aacute； its identification, in this region and at the provincial level； oacute； the heavy chain variable of the antibody, (a) CDR1 includes the sequence of amino acid and sleeping drug； the cidos described in Aacute； such as SEQ ID No.62 or SEQ ID No.63, (b) CDR2 includes ammonia water and ampere sequence； Aacute； cidos； called SEQ ID No: 13 or SEQ ID No: 14； and (c) CDR3 includes ammonia water and ampere sequence； Aacute； cidos； and UN an amp； Aacute； called SEQ ID No: 15 or SEQ ID No: 16 with their identifications； lt； / P gt；<；p>；LA PRESENTE INVENCIÓ；N SE REFIERE A UN ANTICUERPO ANTI-RECEPTOR DE TRANSFERRINA HUMANA O UN ANÁ；LOGO DEL MISMO, EN DONDE EN LA REGIÓ；N VARIABLE DE CADENA PESADA DEL ANTICUERPO, (A) LA CDR1 COMPRENDE LA SECUENCIA DE AMINOÁ；CIDOS DESCRITA COMO SEQ ID NO: 62 O SEQ ID NO: 63, (B) LA CDR2 COMPRENDE LA SECUENCIA DE AMINOÁ；CIDOS DESCRITA COMO SEQ ID NO: 13 O SEQ ID NO: 14, Y (C) LA CDR3 COMPRENDE LA SECUENCIA DE AMINOÁ；CIDOS DESCRITA COMO SEQ ID NO: 15 O SEQ ID NO: 16, Y UN ANÁ；LOGO DEL MISMO.<；/p>；
